PMID- 31232176
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1557-9042 (Electronic)
IS  - 0897-7151 (Linking)
VI  - 36
IP  - 24
DP  - 2019 Dec 15
TI  - MIC-1/GDF15 Overexpression Is Associated with Increased Functional Recovery in 
      Traumatic Spinal Cord Injury.
PG  - 3410-3421
LID - 10.1089/neu.2019.6421 [doi]
AB  - Spinal cord injury (SCI) has devastating consequences, with limited therapeutic 
      options; therefore, improving its functional outcome is a major goal. The outcome 
      of SCI is contributed to by neuroinflammation, which may be a target for improved 
      recovery and quality of life after injury. Macrophage inhibitory 
      cytokine-1/growth differentiation factor 15 (MIC-1/GDF15) has been identified as 
      a potential novel therapy for central nervous system (CNS) injury because it is 
      an immune regulatory cytokine with neurotrophic properties. Here we used 
      MIC-1/GDF15 knockout (KO) and overexpressing/transgenic (Tg) and wild type (WT) 
      animals to explore its putative therapeutic benefits in a mouse model of 
      contusive SCI. MIC-1/GDF15 Tg mice had superior locomotor recovery and reduced 
      secondary tissue loss at 28 days compared with their KO and WT counterparts. 
      Overexpression of MIC-1/GDF15 coincided with increased expression of monocyte 
      chemoattractant protein-1 (MCP-1)/C-C Motif Chemokine Ligand 2 (CCL2) at the 
      lesion site (28 days post-SCI) and enhanced recruitment of inflammatory cells to 
      the injured spinal cord. This inflammatory cellular infiltrate included an 
      increased frequency of macrophages and dendritic cells (DCs) that mostly preceded 
      recruitment of cluster of differentiation (CD)4(+) and CD8(+) T cells. 
      Collectively, our findings suggest hat MIC-1/GDF15 is associated with beneficial 
      changes in the clinical course of SCI that are characterized by altered 
      post-injury inflammation and improved functional outcome. Further investigation 
      of MIC-1/GDF15 as a novel therapeutic target for traumatic SCI appears warranted.
FAU - Hassanpour Golakani, Masoud
AU  - Hassanpour Golakani M
AD  - St. Vincent's Centre for Applied Medical Research (AMR), St Vincent's Hospital 
      and University of New South Wales (UNSW), Sydney, New South Wales, Australia.
AD  - The Neuroinflammation Research Group, Centre for Immunology and Allergy Research, 
      Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
      Wales, Australia.
FAU - Mohammad, Mohammad G
AU  - Mohammad MG
AD  - Department of Medical Laboratory Sciences, College of Health Sciences and Sharjah 
      Institute for Medical Research, University of Sharjah, Sharjah, United Arab 
      Emirates. Faculty of Medicine, University of Queensland, Brisbane, Queensland, 
      Australia.
FAU - Li, Hui
AU  - Li H
AD  - St. Vincent's Centre for Applied Medical Research (AMR), St Vincent's Hospital 
      and University of New South Wales (UNSW), Sydney, New South Wales, Australia.
AD  - The Neuroinflammation Research Group, Centre for Immunology and Allergy Research, 
      Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
      Wales, Australia.
FAU - Gamble, Joanne
AU  - Gamble J
AD  - The Neuroinflammation Research Group, Centre for Immunology and Allergy Research, 
      Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
      Wales, Australia.
FAU - Breit, Samuel N
AU  - Breit SN
AD  - St. Vincent's Centre for Applied Medical Research (AMR), St Vincent's Hospital 
      and University of New South Wales (UNSW), Sydney, New South Wales, Australia.
FAU - Ruitenberg, Marc J
AU  - Ruitenberg MJ
AD  - School of Biomedical Sciences, Faculty of Medicine, University of Queensland, 
      Brisbane, Queensland, Australia.
FAU - Brown, David A
AU  - Brown DA
AD  - St. Vincent's Centre for Applied Medical Research (AMR), St Vincent's Hospital 
      and University of New South Wales (UNSW), Sydney, New South Wales, Australia.
AD  - The Neuroinflammation Research Group, Centre for Immunology and Allergy Research, 
      Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
      Wales, Australia.
AD  - Department of Immunopathology, Institute for Clinical Pathology and Medical 
      Research-New South Wales Health Pathology, Westmead Hospital, Sydney, New South 
      Wales, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190801
PL  - United States
TA  - J Neurotrauma
JT  - Journal of neurotrauma
JID - 8811626
RN  - 0 (Gdf15 protein, mouse)
RN  - 0 (Growth Differentiation Factor 15)
SB  - IM
MH  - Animals
MH  - Female
MH  - Gene Expression
MH  - Growth Differentiation Factor 15/*biosynthesis/genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Recovery of Function/*physiology
MH  - Spinal Cord Injuries/genetics/*metabolism/pathology
MH  - Thoracic Vertebrae/injuries
OTO - NOTNLM
OT  - MIC-1/GDF15
OT  - SCI
OT  - neuroinflammation
EDAT- 2019/06/25 06:00
MHDA- 2020/11/11 06:00
CRDT- 2019/06/25 06:00
PHST- 2019/06/25 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2019/06/25 06:00 [entrez]
AID - 10.1089/neu.2019.6421 [doi]
PST - ppublish
SO  - J Neurotrauma. 2019 Dec 15;36(24):3410-3421. doi: 10.1089/neu.2019.6421. Epub 
      2019 Aug 1.